Skip to main content
HLS Therapeutics Inc. logo

HLS Therapeutics Inc. — Investor Relations & Filings

Ticker · HLS ISIN · US40390B3078 LEI · 549300QKXFY1J71L2D68 TSX Wholesale and retail trade
Open in API
Filings indexed 364 across all filing types
Latest filing 2022-05-05 Interim / Quarterly Rep…
Country CA Canada
Listing TSX HLS

About HLS Therapeutics Inc.

https://hlstherapeutics.com/

HLS Therapeutics Inc. is a specialty pharmaceutical company focused on the acquisition and commercialization of branded medicines across North America. The company targets products that address unmet needs, primarily in the treatment of psychiatric disorders and cardiovascular disease/risk reduction. Its commercial-stage portfolio includes CLOZARIL® (clozapine) for psychiatric disorders and VASCEPA® (icosapent ethyl) for cardiovascular risk reduction. HLS also commercializes NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid/ezetimibe combination) for the reduction of LDL-cholesterol in patients at risk of cardiovascular disease. HLS ensures reliable market access to these essential therapies by sourcing products directly from originators and best-in-class manufacturing partners.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Unaudited Condensed Interim Consolidated Financial Statements' for HLS Therapeutics Inc. for the three months ended March 31, 2022. It contains detailed financial statements including the statement of financial position, statement of loss, statement of comprehensive loss, statement of changes in shareholders' equity, and statement of cash flows. The document also includes notes to the financial statements, basis of preparation, accounting policies, and other disclosures typical of an interim financial report. The presence of actual financial data and analysis for a period shorter than a full fiscal year (quarterly) confirms this is an Interim / Quarterly Report. The document is approximately 15,000 characters, indicating it is a full report, not just an announcement or certification. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). Q1 2022
2022-05-05 English
News release - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of HLS Therapeutics' Q1 Fiscal 2022 financial results, including revenue, EBITDA, net loss, cash flow, and operational highlights for the quarter ended March 31, 2022. It contains substantive financial data, segmented revenue, operating expenses, and financial position statements. It also mentions a conference call to discuss these results. The presence of comprehensive financial statements and analysis for a quarter strongly indicates this is an Interim / Quarterly Report. The document is about 15,000 characters long, which is consistent with a full report rather than a brief announcement or press release. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2022
2022-05-05 English
News release - English.pdf
Regulatory Filings
2022-04-28 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the completion of a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for public market reimbursement of the drug Vascepa. It includes updated peak-year sales estimates and mentions a conference call to discuss the announcement. The content focuses on a business update related to product listing agreements and market access, not on detailed financial results or comprehensive financial statements. It also includes a conference call announcement, which suggests the document is primarily an announcement of a corporate development and related investor communication. There is no detailed financial report, audit, or regulatory filing presented. The presence of a conference call to discuss the announcement aligns with the characteristics of a Capital/Financing Update or business development update. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-04-26 English
News release - English.pdf
Investor Presentation Classification · 85% confidence The document is a press release announcing that HLS Therapeutics will present at the 2022 Bloom Burton & Co. Healthcare Investor Conference. It includes details about the presentation date, time, webcast link, and background information about the company and the conference. There is no financial data, no detailed investor presentation content, nor any regulatory filing or report attached. The document is essentially an announcement of an upcoming investor presentation event, not the presentation itself or a financial report. Therefore, the most appropriate classification is Investor Presentation (IP) because it relates to a detailed presentation for investors focusing on financials, strategy, and market position, even though the actual presentation content is not included here, the announcement is about the presentation event itself, which fits best under IP rather than RPA or RNS.
2022-04-25 English
Notice of the meeting and record date - English.pdf
AGM Information Classification · 90% confidence The document is a notice from Computershare to Canadian Securities Regulatory Authorities regarding the upcoming Annual General Meeting (AGM) of HLS Therapeutics Inc. It provides details about the meeting type, record dates, meeting date, location, and proxy material delivery. The document does not contain any financial data, management discussion, voting results, or detailed report content. It is a notification about the AGM logistics rather than the AGM materials themselves or voting results. Therefore, it fits best as an AGM Information (AGM-R) filing, which covers presentations and materials shared during the AGM or related notices about the AGM.
2022-04-14 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.